Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder

Regeneron Pharmaceuticals will share in development of Tessera Therapeutics’ TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). Other companies developing genetic medicines for this rare disease include Beam Therapeutics, Wave Life Sciences, Korro Bio, and AIRNA. The post Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver &…

Read More

Section 1115 Waiver Watch: A Look at the Use of Contingency Management to Address Stimulant Use Disorder

Contingency management is an evidence-based psychosocial intervention that uses motivational incentives, such as vouchers or gift cards, to encourage recovery behaviors like stimulant abstinence and treatment session (e.g., cognitive behavioral therapy, group therapy) attendance. The Biden administration has approved four state contingency management waivers (California, Delaware, Montana, and Washington); three additional state contingency management requests…

Read More

Hackensack Meridian Health Launches Trial of Canine-Powered Cancer Detection

Hackensack Meridian Health launched a clinical trial with Israeli startup SpotitEarly, which is developing a cancer test that combines AI with trained dogs to analyze patients’ breath. The study aims to validate this noninvasive approach alongside traditional screenings, potentially enabling earlier and more accessible cancer detection. The post Hackensack Meridian Health Launches Trial of Canine-Powered…

Read More